SCHEMBL633261

SCHEMBL633261

Clc1nc(Cl)c2c(n1)CCC2

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACHE P22303 10/20 0.43
MAPK1 P28482 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
BPTF Q12830 1/20 0.43
NSD2 O96028 1/20 0.42
GRIN1 Q05586 5/20 0.37
GRIN2A Q12879 5/20 0.37
BCHE P06276 5/20 0.37
KDM4E B2RXH2 2/20 0.35
POLB P06746 1/20 0.33
RECQL P46063 1/20 0.33
CASP6 P55212 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CHRM1 P11229 1/20 0.33
EPHX2 P34913 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30777931 1.00 ACHE (0.43) ACHEMAPK1MEN1KMT2ABPTF
SCHEMBL1819184 0.95 MAPK1 (0.47) ACHEMAPK1MEN1KMT2ABPTF
SCHEMBL29466623 0.95 MAPK1 (0.47) ACHEMAPK1MEN1KMT2ABPTF
SCHEMBL16136206 0.93 MAPK1 (0.46) ACHEMAPK1MEN1KMT2ABPTF
SCHEMBL15831715 0.93 MAPK1 (0.46) ACHEMAPK1MEN1KMT2ABPTF
SCHEMBL23816987 0.93 MAPK1 (0.46) ACHEMAPK1MEN1KMT2ABPTF
SCHEMBL31095398 0.93 MAPK1 (0.46) ACHEMAPK1MEN1KMT2ABPTF
SCHEMBL21963334 0.78 MAPK1 (0.48) ACHEMAPK1MEN1KMT2ABPTF
SCHEMBL1586850 0.77 KDM4E (0.53) ACHEMAPK1MEN1KMT2ABPTF
SCHEMBL1069076 0.77 KDM4E (0.41) ACHEMAPK1MEN1KMT2ABPTF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 359 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-11292854-A None JP disclosed
US-12637458-B2 Imidazo[1,2-a]pyridine compounds and their use in therapy IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2026-05-26 US disclosed
EP-4142732-B1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2026-04-22 EP disclosed
EP-4724430-A1 CONDENSED AZINES AS INHIBITORS OF CYCLIC ADP RIBOSE HYDROLASE Flagship Pioneering Innovations VI, LLC (US) 2026-04-15 EP disclosed
US-20260092053-A1 KHK INHIBITORS GILEAD SCIENCES INC (US) 2026-04-02 US disclosed
EP-4681774-A2 KHK INHIBITORS Gilead Sciences, Inc. (US) 2026-01-21 EP disclosed
EP-4313967-B1 KHK INHIBITORS GILEAD SCIENCES INC (US) 2025-11-12 EP disclosed
EP-4635949-A1 SUBSTITUTED TETRAHYDROCYCLOPENTYL[C]PYRROLE DERIVATIVE, PREPARATION METHOD, INTERMEDIATE AND USE THEREOF Jiangsu NHWA Pharmaceutical Co., Ltd (CN) 2025-10-22 EP disclosed
US-12410160-B2 KHK inhibitors GILEAD SCIENCES, INC. (US) 2025-09-09 US disclosed
US-20250230155-A1 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS VANDERBILT UNIVERSITY 2025-07-17 US disclosed
US-20070027156-A1 Crf antagonists and heterobicyclic compounds ONO PHARMACEUTICAL CO., LTD. (JP) 2007-02-01 US disclosed
EP-1666468-A1 CRF ANTAGONISTS AND HETEROBICYCLIC COMPOUNDS ONO PHARMACEUTICAL CO., LTD. (JP) 2006-06-07 EP disclosed
US-6951866-B2 Bicyclic pyrimidine compounds and therapeutic use thereof SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-10-04 US disclosed
EP-1110951-B1 PYRIMIDINE DERIVATIVES SUMITOMO PHARMA (JP) 2004-05-19 EP disclosed
US-20030105323-A1 Pyrimidine derivative SUMITOMO PHARMACEUTICALS COMPANY LIMITED 2003-06-05 US disclosed
US-6458798-B1 HAS AN INHIBITORY ACTIVITY OF PRODUCTION OF TH2 TYPE CYTOKINES SUCH AS IL-4, IL-5, ETC., AND IS USEFUL AS AN THERAPEUTIC AGENT FOR ALLERGIC DISEASES, AUTOIMMUNE DISEASES SUCH AS SYSTEMIC LUPUS ERYTHEMATHOSUS, ETC., AND ACQUIRED SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-10-01 US disclosed
EP-1110951-A1 PYRIMIDINE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-06-27 EP disclosed
JP-H11292854-A NOVEL PYRIMIDINE DERIVATIVE KANEBO LTD 1999-10-26 JP disclosed
US-5416081-A Antibiotics as bactericides LUCKY LIMITED (KR) 1995-05-16 US disclosed
EP-0604920-A1 Novel cephalosporin compounds LUCKY LTD. (KR) 1994-07-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092053-A1 KHK INHIBITORS KHK, SLC5A2, HK1 ACHE 4271/4885MAPK1 398/4885MEN1 4138/4885
US-12410160-B2 KHK inhibitors KHK, KHDRBS1, NADK ACHE 4545/4885MAPK1 1141/4885MEN1 2989/4885
US-20070027156-A1 Crf antagonists and heterobicyclic compounds CRHR2, CRHR1, CRH ACHE 3319/4885MAPK1 2539/4885MEN1 3596/4885
US-20030105323-A1 Pyrimidine derivative IL5, IL4, IL15 ACHE 4681/4885MAPK1 639/4885MEN1 3390/4885
US-12637458-B2 Imidazo[1,2-a]pyridine compounds and their use in therapy OGFR, CBR3, CBR1 ACHE 1402/4885MAPK1 1047/4885MEN1 1503/4885
US-20250230155-A1 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS CHRM5, CHRM4, CHRM1 ACHE 22/4885MAPK1 1823/4885MEN1 2532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.